keyword
MENU ▼
Read by QxMD icon Read
search

Advanced prostate cancer

keyword
https://www.readbyqxmd.com/read/29775743/redox-regulation-of-protein-kinase-c-by-selenometabolites-and-selenoprotein-thioredoxin-reductase-limits-cancer-prevention-by-selenium
#1
REVIEW
Rayudu Gopalakrishna, Usha Gundimeda, Sarah Zhou, Bui Helena, Arne Holmgren
The cancer-preventive mechanism of selenium should address the way low concentrations of selenometabolites react with cellular targets without being diffused from the sites of generation, the way selenium selectively kills tumor cells, and the intriguing U-shaped curve that is seen with dietary supplementation of selenium and cancer prevention. Protein kinase C (PKC), a receptor for tumor promoters, is well suited for this mechanism. Due to the catalytic redox cycle, low concentrations of methylselenol, a postulated active metabolite of selenium, react with the tumor-promoting lipid hydroperoxide bound to PKC to form methylseleninic acid (MSA), which selectively reacts with thiol residues present within the vicinity of the PKC catalytic domain to inactivate it...
May 15, 2018: Free Radical Biology & Medicine
https://www.readbyqxmd.com/read/29775158/microrna-expression-in-tumour-tissue-and-plasma-in-patients-with-newly-diagnosed-metastatic-prostate-cancer
#2
Ahmed Hussein Zedan, Torben Frøstrup Hansen, Jannie Assenholt, Mindaugas Pleckaitis, Jonna Skov Madsen, Palle Jörn Sloth Osther
Prostate cancer is the most common cancer among men in the western world. Clinical practice is continuously challenged by the pitfalls of the available diagnostic tools. microRNAs may represent promising biomarkers in many types of human cancers, including prostate cancer. The aim of this study was to investigate microRNA expression in tumour tissue and matched plasma in a cohort of patients with primary metastatic prostate cancer. The relative expression of 12 microRNAs was assessed in diagnostic needle biopsies from the prostate and matched plasma samples in two prospective cohorts (screening cohorts) comprising 21 patients with metastatic prostate cancer and 25 control patients...
May 2018: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/29774804/patient-preferences-and-urologist-judgments-on-prostate-cancer-therapy-in-japan
#3
Masahiko Nakayama, Hisanori Kobayashi, Masateru Okazaki, Keiichiro Imanaka, Kazutake Yoshizawa, Jörg Mahlich
The purpose of the present study is to investigate the concordance of treatment preferences between patients and physicians in prostate cancer (PCa) in Japan. An internet-based discrete choice experiment was conducted. Patients and physicians were asked to select their preferred treatment from a pair of hypothetical treatments consisting of four attributes: quality of life (QOL), treatment effectiveness, side effects, and accessibility of treatment. The data were analyzed using a conditional logistic regression model to calculate coefficients and the relative importance (RI) of each attribute...
May 1, 2018: American Journal of Men's Health
https://www.readbyqxmd.com/read/29772621/-a-case-of-choroidal-and-brain-metastases-from-castration-resistant-prostate-cancer
#4
Shuko Yoneyama, Takahiko Watanabe, Tatsuaki Onuki, Kazuro Yabuki, Kotaro Suzuki
Choroidal and central nervous system metastases from prostate cancer are extremely rare. We report a case of choroidal and brain metastases from castration-resistant prostate cancer (CRPC). A 75-year-old male patient with metastatic CRPC presented with a 1-week history of a decrease in visual acuity in his left eye. An ophthalmoscopic examination revealed a choroidal tumor, 4 disc diameters across with serious retinal detachment. He was diagnosed with metastatic choroidal tumor from examination and patient's background...
April 2018: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/29772510/dkk1-and-kremen-expression-predicts-the-osteoblastic-response-to-bone-metastasis
#5
Katrina L Clines, Gregory A Clines
Bone metastasis is a complication of advanced breast and prostate cancer. Tumor-secreted Dickkopf homolog 1 (DKK1), an inhibitor of canonical Wnt signaling and osteoblast differentiation, was proposed to regulate the osteoblastic response to metastatic cancer in bone. The objectives of this study were to compare DKK1 expression with the in vivo osteoblastic response in a panel of breast and prostate cancer cell lines, and to discover mechanisms that regulate cancer DKK1 expression. DKK1 expression was highest in MDA-MB-231 and PC3 cells that produce osteolytic lesions, and hence a suppressed osteoblastic response, in animal models of bone metastasis...
May 14, 2018: Translational Oncology
https://www.readbyqxmd.com/read/29771696/the-future-of-anesthesia-for-interventional-radiology
#6
Annie Amin, Jason Scott Lane
PURPOSE OF REVIEW: To review novel procedures in interventional radiology and describe anesthetic implications. RECENT FINDINGS: Noninvasive treatment options for patients who are nonsurgical candidates are on the rise. The complication rate for patients receiving anesthesia in the interventional radiology suite is higher than other nonoperating room anesthetizing locations. The investigative use of catheter-directed thrombolysis for acute submassive pulmonary embolism will likely lead to an increased demand for anesthesia assistance...
May 15, 2018: Current Opinion in Anaesthesiology
https://www.readbyqxmd.com/read/29771460/targeting-prostate-cancer-prostate-specific-membrane-antigen-based-diagnosis-and-therapy
#7
REVIEW
Till Wüstemann, Uwe Haberkorn, John Babich, Walter Mier
The high incidence rates of prostate cancer (PCa) raise demand for improved therapeutic strategies. Prostate tumors specifically express the prostate-specific membrane antigen (PSMA), a membrane-bound protease. As PSMA is highly overexpressed on malignant prostate tumor cells and as its expression rate correlates with the aggressiveness of the disease, this tumor-associated biomarker provides the possibility to develop new strategies for diagnostics and therapy of PCa. Major advances have been made in PSMA targeting, ranging from immunotherapeutic approaches to therapeutic small molecules...
May 17, 2018: Medicinal Research Reviews
https://www.readbyqxmd.com/read/29770311/-super-active-surveillance-mri-ultrasound-fusion-biopsy-and-ablation-for-less-invasive-management-of-prostate-cancer
#8
REVIEW
Jonathan B Bloom, Samuel A Gold, Graham R Hale, Kareem N Rayn, Vikram K Sabarwal, Ivane Bakhutashvili, Vladimir Valera, Baris Turkbey, Peter A Pinto, Bradford J Wood
Multiparametric magnetic resonance imaging (mpMRI) of the prostate has allowed clinicians to better visualize and target suspicious lesions during biopsy. Targeted prostate biopsies give a more accurate representation of the true cancer volume and stage so that appropriate treatment or active surveillance can be selected. Advances in technology have led to the development of MRI and ultrasound fusion platforms used for targeted biopsies, monitoring cancer progression, and more recently for the application of focal therapy...
April 2018: Gland Surgery
https://www.readbyqxmd.com/read/29770305/the-prostate-cancer-focal-therapy
#9
REVIEW
Filippo Pesapane, Francesca Patella, Enrico Maria Fumarola, Edoardo Zanchetta, Chiara Floridi, Gianpaolo Carrafiello, Chloë Standaert
Despite prostate cancer (PCa) is the leading form of non-cutaneous cancer in men, most patients with PCa die with disease rather than of the disease. Therefore, the risk of overtreatment should be considered by clinicians who have to distinguish between patients with high risk PCa (who would benefit from radical treatment) and patients who may be managed more conservatively, such as through active surveillance or emerging focal therapy (FT). The aim of FT is to eradicate clinically significant disease while protecting key genito-urinary structures and function from injury...
April 2018: Gland Surgery
https://www.readbyqxmd.com/read/29769644/translational-models-of-prostate-cancer-bone-metastasis
#10
REVIEW
Richard B Berish, Aymon N Ali, Patrick G Telmer, John A Ronald, Hon S Leong
Metastatic disease is the principal cause of prostate-cancer-related mortality. Our ability to accurately recapitulate the spread of prostate cancer to bone - the most common site of metastasis - is critical to the development of novel metastasis-directed therapies. Several translational models of prostate cancer bone metastasis have been developed, including animal models, cell line injection models, 3D in vitro models, bone implant models, and patient-derived xenograft models. The use of these models has led to numerous advances in elucidating the molecular mechanisms of metastasis and innovations in targeted therapy...
May 16, 2018: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29769196/an-in-vivo-screen-identifies-pygo2-as-a-driver-for-metastatic-prostate-cancer
#11
Xin Lu, Xiaolu Pan, Chang-Jiun Wu, Di Zhao, Shan Feng, Yong Zang, Rumi Lee, Sunada Khadka, Samirkumar B Amin, Eun-Jung Jin, Xiaoying Shang, Pingna Deng, Yanting Luo, William R Morgenlander, Jacqueline Weinrich, Xuemin Lu, Shan Jiang, Qing Chang, Nora M Navone, Patricia Troncoso, Ronald A DePinho, Y Alan Wang
Advanced prostate cancer displays conspicuous chromosomal instability and rampant copy number aberrations, yet the identity of functional drivers resident in many amplicons remain elusive. Here, we implemented a functional genomics approach to identify new oncogenes involved in prostate cancer progression. Through integrated analyses of focal amplicons in large prostate cancer genomic and transcriptomic datasets as well as genes upregulated in metastasis, 276 putative oncogenes were enlisted into an in vivo gain-of-function tumorigenesis screen...
May 16, 2018: Cancer Research
https://www.readbyqxmd.com/read/29766246/comparison-of-68-ga-ga-psma-11-pet-ct-with-18-f-naf-pet-ct-in-the-evaluation-of-bone-metastases-in-metastatic-prostate-cancer-patients-prior-to-radionuclide-therapy
#12
Christian Uprimny, Anna Svirydenka, Josef Fritz, Alexander Stephan Kroiss, Bernhard Nilica, Clemens Decristoforo, Roland Haubner, Elisabeth von Guggenberg, Sabine Buxbaum, Wolfgang Horninger, Irene Johanna Virgolini
AIM: The purpose of this study was to investigate the diagnostic performance of 68 Ga-PSMA-11 PET/CT in the evaluation of bone metastases in metastatic prostate cancer (PC) patients scheduled for radionuclide therapy in comparison to [18 F]sodium fluoride (18 F-NaF) PET/CT. METHODS: Sixteen metastatic PC patients with known skeletal metastases, who underwent both 68 Ga-PSMA-11 PET/CT and 18 F-NaF PET/CT for assessment of metastatic burden prior to radionuclide therapy, were analysed retrospectively...
May 16, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29765457/high-lncrna-hulc-expression-is-associated-with-poor-prognosis-and-promotes-tumor-progression-by-regulating-epithelial-mesenchymal-transition-in-prostate-cancer
#13
Pengyi Zheng, Huibing Li, Po Xu, Xiaohui Wang, Zhenguo Shi, Qingjiang Han, Zhijun Li
Introduction: Recently, increasing evidence has shown that long non-coding RNAs (lncRNAs) play critical roles in tumor progression and development. However, the expression pattern and biological function of lncRNA HULC (highly upregulated in liver cancer) in prostate cancer (PCa) remain largely unclear. Material and methods: The expression of lncRNA HULC in 53 paired PCa tissues and cell lines was detected by quantitative real-time polymerase chain reaction (qRT-PCR)...
April 2018: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/29765147/systemic-treatments-for-high-risk-localized-prostate-cancer
#14
REVIEW
Géraldine Pignot, Denis Maillet, Emmanuel Gross, Philippe Barthelemy, Jean-Baptiste Beauval, Friederike Constans-Schlurmann, Yohann Loriot, Guillaume Ploussard, Paul Sargos, Marc-Olivier Timsit, Sébastien Vincendeau, Gilles Pasticier, Delphine Borchiellini
The majority of patients with prostate cancer who later develop lethal metastatic disease have high-risk localized disease at presentation, emphasizing the importance of effective treatment strategies at this stage. Multimodal treatment approaches that combine systemic and local therapies offer a promising strategy for improving the clinical outcomes of patients with high-risk localized prostate cancer. Combinations of neoadjuvant and adjuvant chemotherapy, hormonal therapy, or chemohormonal therapy are considered to be the standard of care in most solid tumours and should be investigated in the future for the treatment of prostate cancer to improve patient outcomes...
May 15, 2018: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29764515/long-term-outcome-of-a-moderately-hypofractionated-intensity-modulated-radiotherapy-approach-using-an-endorectal-balloon-for-patients-with-localized-prostate-cancer
#15
Bin S Teh, Gary D Lewis, Weiyuan Mai, Ramiro Pino, Hiromichi Ishiyama, Edward Brian Butler
BACKGROUND: Technical advances in radiotherapy delivery have simultaneously enabled dose escalation and enhanced bladder and rectal sparing. However, the optimal radiation fractionation regimen for localized prostate cancer is unclear. Laboratory and clinical evidence suggest that hypofractionation may improve the therapeutic ratio of radiotherapy. We report our institutional outcomes using moderately hypofractionated, intensity-modulated radiotherapy (IMRT), and an endorectal balloon, with emphasis on long-term biochemical control and treatment-related adverse events in patients with localized prostate cancer...
April 17, 2018: Cancer communications
https://www.readbyqxmd.com/read/29764181/symptom-clusters-using-the-eortc-qlq-c15-pal-in-palliative-radiotherapy
#16
Vithusha Ganesh, Liying Zhang, Bo Angela Wan, Leah Drost, May Tsao, Elizabeth Barnes, Carlo DeAngelis, Hans Chung, Patrick Diaz, Edward Chow
BACKGROUND: Patients with advanced cancer often experience a multitude of symptoms. Due to the potential interrelation of symptoms, symptom clusters of 2 or more concurrent symptoms have been advocated for use in the palliative setting to provide better management of symptoms. METHODS: The principal component analysis (PCA), exploratory factor analysis (EFA) and hierarchal cluster analysis (HCA) were conducted on responses to items 1-14 in the European Organisation for Research and Treatment of Cancer Quality of Life-C15-Palliative (EORTC QLQ-C15-PAL) at baseline and days 5 and 10 following RT...
April 2018: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/29762619/isolation-and-genome-sequencing-of-individual-circulating-tumor-cells-using-hydrogel-encapsulation-and-laser-capture-microdissection
#17
Emily S Park, Justin P Yan, Richard A Ang, Jeong Hyun Lee, Xiaoyan Deng, Simon P Duffy, Kevin Beja, Matti Annala, Peter C Black, Kim N Chi, Alexander W Wyatt, Hongshen Ma
Circulating tumor cells (CTCs) are malignant cells released into the bloodstream with the potential to form metastases in secondary sites. These cells, acquired non-invasively, represent a sample of highly relevant tumor tissue that is an alternative to difficult and low-yield tumor biopsies. In recent years, there has been growing interest in genomic profiling of CTCs to enable longitudinal monitoring of the tumor's adaptive response to therapy. However, due to their extreme rarity, genotyping CTCs has proved challenging...
May 15, 2018: Lab on a Chip
https://www.readbyqxmd.com/read/29762048/theranostics-of-prostate-cancer-from-molecular-imaging-to-precision-molecular-radiotherapy-targeting-the-prostate-specific-membrane-antigen
#18
Harshad R Kulkarni, Aviral Singh, Thomas Langbein, Christiane Schuchardt, Dirk Mueller, Jingjing Zhang, Coline Lehmann, Richard P Baum
Alterations at the molecular level are a hallmark of cancer. Prostate cancer is associated with the overexpression of prostate specific membrane antigen (PSMA) in a majority of cases, predominantly in advanced tumors, increasing with the grade or Gleason's score. PSMA can be selectively targeted using radiolabelled PSMA ligands. These small molecules binding the PSMA can be radiolabelled with gamma-emitters like 99m Tc and 111 In or positron emitters like 68 Ga and 18 F for diagnosis as well as with their theranostic pairs such as 177 Lu (beta-emitter) or 225 Ac (alpha-emitter) for therapy...
May 15, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29761524/the-24th-annual-prostate-cancer-foundation-scientific-retreat-report
#19
REVIEW
Andrea K Miyahira, Howard R Soule
INTRODUCTION: The 24th Annual Prostate Cancer Foundation (PCF) Scientific Retreat was held from October 5-7, 2017, at the Omni Shoreham Hotel in Washington, DC. METHODS: The PCF Scientific Retreat is a scientific conference that specifically focuses on cutting edge research deemed to have significant promise for accelerating advances in prostate cancer biology and treatment. RESULTS: Themes highlighted at this year's meeting included: (i) new understandings in prostate cancer biology and disease progression; (ii) new mechanisms and treatment targets in advanced prostate cancer; (iii) advances in precision medicine genomics, germline genetics, and selection of targeted therapies; (iv) PSMA-targeted agents for PET imaging and radionuclide therapy; (v) approaches for improving the efficacy of immunotherapy in prostate cancer; (vi) applications of 3D Genomics in prostate cancer research; and (vii) potential applications of artificial intelligence in prostate cancer...
May 15, 2018: Prostate
https://www.readbyqxmd.com/read/29761522/thrombotic-characteristics-of-extracellular-vesicles-derived-from-prostate-cancer-cells
#20
Hassan A Al Saleh, Sandor Haas-Neill, Ali Al-Hashimi, Anil Kapoor, Bobby Shayegan, Richard C Austin, Khalid Al-Nedawi
BACKGROUND: Prostate cancer (PC) patients in advanced stages of the disease have high risk of blood coagulation complications. The procoagulant molecule Tissue factor (TF), and the fibrinolysis inhibitor plasminogen activator inhibitor-1 PAI-1 play important role in this complication. Extracellular vesicles (EV) shed from cancer cells may contribute to the regulation of TF and PAI-1. The procoagulant activity of EV can be associated with the oncogenic and metastatic characteristics of their cells...
May 15, 2018: Prostate
keyword
keyword
45030
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"